Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada

[21] Dinant GJ(1999)Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of osteoporotic fractures research group J Bone Miner Res. 166 818-23

[22] Camacho PM(2017)Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians Ann Intern Med 5 136-82

[23] Petak SM(1995)Cost-effectiveness of fracture prevention in established osteoporosis Osteoporos Int 30 1745-1290

[24] Binkley N(2019)Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom Osteoporos Int 18 9-97

[25] Eastell R(2007)Cost-effectiveness of the treatment and prevention of osteoporosis-a review of the literature and a reference model Osteoporos Int. 22 967-13

[26] Rosen CJ(2011)Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis Osteoporos Int. 39 1276-14

[27] Black DM(2017)A model for assessing the clinical and economic benefits of bone-forming agents for reducing fractures in postmenopausal women at high, near-term risk of osteoporotic fracture Clin Ther 11 485-1630

[28] Cheung AM(2013)Cost-effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US Appl Health Econ Health Policy. 59 105-2938

[29] Murad MH(2014)Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective Bone. 93 1-566

[30] Shoback D(2013)Health technology assessment in osteoporosis Calcif Tissue Int. 104 1623-E161

[21] Dinant GJ(1999)Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of osteoporotic fractures research group J Bone Miner Res. 166 818-23

[22] Camacho PM(2017)Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians Ann Intern Med 5 136-82

[23] Petak SM(1995)Cost-effectiveness of fracture prevention in established osteoporosis Osteoporos Int 30 1745-1290

[24] Binkley N(2019)Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom Osteoporos Int 18 9-97

[25] Eastell R(2007)Cost-effectiveness of the treatment and prevention of osteoporosis-a review of the literature and a reference model Osteoporos Int. 22 967-13

[26] Rosen CJ(2011)Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis Osteoporos Int. 39 1276-14

[27] Black DM(2017)A model for assessing the clinical and economic benefits of bone-forming agents for reducing fractures in postmenopausal women at high, near-term risk of osteoporotic fracture Clin Ther 11 485-1630

[28] Cheung AM(2013)Cost-effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US Appl Health Econ Health Policy. 59 105-2938

[29] Murad MH(2014)Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective Bone. 93 1-566

[30] Shoback D(2013)Health technology assessment in osteoporosis Calcif Tissue Int. 104 1623-E161